ProteinQure uses artificial intelligence and physics based methods for the computational design of de-novo protein therapeutics. Antibodies, peptides, and other protein-based drugs are capable of targeting a broad range of biological targets outside the scope of traditional small molecule therapeutics. Due to their structural complexity, size and dynamic flexibility, computational methods for biologics are just now becoming possible. Our computational platform enables the world leading drug discovery companies to advance their early stage programs and is less data dependent than the alternatives.
Using ProteinStudio, our proprietary technology for computational peptide design, we developed high-affinity SORT1 targeting peptides that efficiently internalize and shuttle to the lysosome via a SORT1-dependent mechanism. These peptides serve as a platform for cargo delivery into SORT1 expressing cells. We are now currently developing the platform for various therapeutic applications including the delivery of cytotoxic agents, radioisotopes, and oligonucleotides. Read more in our whitepaper.
Read more about our Soritilin platform by clicking here or the graph above.
We are also exploring a breadth of additional opportunities using the ProteinStudio discovery platform to design peptide-based cargo delivery therapeutics targeting antigens with tissue tropism. We are open to working with collaborators interested in delivery to tissues where we’ve already identified receptors with PQStudio platform fit. Current opportunities include kidney, pancreas, cardiomyocytes, and select immune cell lineages.
We are located in downtown Toronto; one of the fastest growing tech hubs in North America. At the heart of the university and life sciences ecosystems, we benefit from great relationships with the surrounding players in AI and biotech.
Interested in learning more? Come talk to us!
Office Address: 119 Spadina Ave Suite 304, Toronto, ON M5V 2L1, Canada
E-Mail: team@proteinqure.com
Web: www.proteinqure.com
Show Google Map